JP2008546833A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546833A5
JP2008546833A5 JP2008519017A JP2008519017A JP2008546833A5 JP 2008546833 A5 JP2008546833 A5 JP 2008546833A5 JP 2008519017 A JP2008519017 A JP 2008519017A JP 2008519017 A JP2008519017 A JP 2008519017A JP 2008546833 A5 JP2008546833 A5 JP 2008546833A5
Authority
JP
Japan
Prior art keywords
muc
based formulation
weeks
subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008519017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546833A (ja
JP5364371B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/002771 external-priority patent/WO2007015171A2/en
Publication of JP2008546833A publication Critical patent/JP2008546833A/ja
Publication of JP2008546833A5 publication Critical patent/JP2008546833A5/ja
Application granted granted Critical
Publication of JP5364371B2 publication Critical patent/JP5364371B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008519017A 2005-06-28 2006-06-27 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法 Expired - Fee Related JP5364371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69423305P 2005-06-28 2005-06-28
US60/694,233 2005-06-28
PCT/IB2006/002771 WO2007015171A2 (en) 2005-06-28 2006-06-27 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012215405A Division JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Publications (3)

Publication Number Publication Date
JP2008546833A JP2008546833A (ja) 2008-12-25
JP2008546833A5 true JP2008546833A5 (enExample) 2009-08-13
JP5364371B2 JP5364371B2 (ja) 2013-12-11

Family

ID=37708986

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008519017A Expired - Fee Related JP5364371B2 (ja) 2005-06-28 2006-06-27 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2012215405A Expired - Fee Related JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2015186321A Pending JP2016014046A (ja) 2005-06-28 2015-09-24 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012215405A Expired - Fee Related JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2015186321A Pending JP2016014046A (ja) 2005-06-28 2015-09-24 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Country Status (16)

Country Link
US (3) US8871250B2 (enExample)
EP (2) EP2366400B1 (enExample)
JP (3) JP5364371B2 (enExample)
CN (2) CN105194650A (enExample)
AR (1) AR054526A1 (enExample)
AU (1) AU2006274651B2 (enExample)
BR (1) BRPI0613510A2 (enExample)
CA (1) CA2613327A1 (enExample)
DK (2) DK1896051T3 (enExample)
ES (2) ES2526344T3 (enExample)
HK (1) HK1219417A1 (enExample)
HU (1) HUE026490T2 (enExample)
PL (2) PL1896051T3 (enExample)
PT (2) PT2366400E (enExample)
TW (2) TWI511738B (enExample)
WO (1) WO2007015171A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
MX2011006562A (es) * 2008-12-17 2011-09-27 Oncothyreon Inc Metodo para elaborar liposomas pequeños.
BRPI1009892A2 (pt) * 2009-03-24 2016-03-15 Transgène S A método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
BRPI1010512A2 (pt) * 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
GB0910751D0 (en) 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
EP2452194B1 (en) 2009-07-10 2015-11-11 Transgene SA Biomarker for selecting patients and related methods
US9346867B2 (en) 2010-04-19 2016-05-24 Sumitomo Bakelite Co., Ltd. Cancer-related glycopeptide epitopes, antibodies and methods of use
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
JP2016520073A (ja) * 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｕｃ−１リポペプチドによるワクチン免疫で肺癌を治療する方法
BR112016000889A2 (pt) * 2013-08-21 2017-12-12 Curevac Ag composição e vacina para tratamento de câncer de próstata
US9467478B1 (en) 2013-12-18 2016-10-11 vIPtela Inc. Overlay management protocol for secure routing based on an overlay network
WO2015099224A1 (ko) 2013-12-26 2015-07-02 주식회사 포스코 압연장치, 연주압연장치 및 방법
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
WO2026011417A1 (en) * 2024-07-12 2026-01-15 The Hong Kong University Of Science And Technology Compositions and methods involving artificial poly (a) sequences

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
ATE72123T1 (de) 1985-04-19 1992-02-15 Wistar Inst Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) * 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
DE69839443D1 (de) * 1997-05-08 2008-06-19 Biomira Inc Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
WO2001018035A2 (en) 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
US7491707B1 (en) 1999-11-15 2009-02-17 Biomira, Inc. Synthetic lipid-a-analogs and uses thereof
CA2404327A1 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
DE60134265D1 (de) * 2000-12-01 2008-07-10 Biomira Inc Herstellung grosser liposome durch infusion in peg
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
EP1572918B1 (en) 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質ａおよび他の炭水化物リガンド類似体
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)

Similar Documents

Publication Publication Date Title
RU2012149618A (ru) Менингококковые полипептиды fhbp
RU2009101387A (ru) Рекомбинантная вирусная вакцина
JP2013502918A5 (enExample)
JP2008531637A5 (enExample)
ATE507840T1 (de) Hilfszusammensetzung für vakzinen, die über die schleimhaut oder durch injektion verabreicht werden
JP2015505309A5 (enExample)
JP2006020648A5 (enExample)
JP2014503172A5 (enExample)
JP2007515393A5 (enExample)
JP2010500399A5 (enExample)
JP2010529026A5 (enExample)
JP2012500001A5 (enExample)
KR20130024888A (ko) 폴리펩티드
JP2008530245A5 (enExample)
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2005537800A5 (enExample)
JP2004535187A (ja) アジュバントとしてのコレラホロトキシンの突然変異形
CA2115839A1 (en) Hla-restricted hepatitis b virus ctl epitopes
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
RU2007139915A (ru) Haemophilus influenzae типа в
JP2008543847A5 (enExample)
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
RU2015100889A (ru) Вакцины для менингококка серогруппы х
CN101754768B (zh) 用作癌症疫苗的存活蛋白肽
Bubenik et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.